GSK plc shows strong progress in its oncology pipeline, highlighted by positive phase 1 results for Mo-Rez in treating platinum-resistant ovarian and endometrial cancers. These promising outcomes support plans for five global pivotal phase 3 trials set to begin in 2026, signaling significant late-stage expansion in oncology. Additionally, GSK's ViiV Healthcare reports superior viral suppression with Cabenuva in HIV treatment, while the company advances acquisitions and registrational data in multiple myeloma and lung cancer. GSK also delivered robust Q2 core financial results and aims to initiate over 20 phase 3 trials in 2026 to drive future growth.
Following GSK's announcement of strong progress in oncology and HIV treatment, the company's shares have gained momentum, rising 3.57% to USD 47.92 as of Oct 15, 2026 03:11 WIB on Pluang. The stock is currently trading well above its 52-week low of USD 43.24, with a market cap of $92.78 billion. Investor interest remains high, reflected in 100% buy orders on the platform at this time.
GSK is forecasted to report a third quarter revenue of £8.82 billion, slightly below consensus, with core earnings per share matching expectations. Weak vaccine sales, particularly Shingrix, are expected to be offset by stronger performance in HIV tr...
The complicated urinary tract infections (cUTI) market is projected to expand steadily through 2036, driven by increasing antimicrobial resistance, higher rates of recurrent and hospital-acquired infections, and more patients with underlying conditio...
